NewsRx

Search our medical news database

Collaborations

Global influenza partnership signed with Sankyo

Published in TB and Outbreaks Week, October 28th, 2003

Biota Holdings Limited announced that it had signed a landmark influenza drug agreement with one of Japan's largest pharmaceutical companies, Sankyo Co., Ltd.

The collaboration and license agreement covers Biota's second-generation influenza compounds (Flunet) and a comparable and competitive Sankyo compound (R118958) that is already in human clinical trials. The agreement consummates a letter of intent that was executed between the companies on May 23, 2003.

The second-generation compounds are longer acting than any currently available flu treatments. While the existing drugs need to be administered twice per day, the new drugs may only need to be...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of TB and Outbreaks Week


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook